Search

Lexicon Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

2.29 -1.72

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.29

Massimo

2.35

Metriche Chiave

By Trading Economics

Entrata

-32M

-33M

Vendite

-20M

692K

EPS

-0.06

Margine di Profitto

-4,742.486

Dipendenti

81

EBITDA

-30M

-29M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+156.41% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-2.7M

1B

Apertura precedente

4.01

Chiusura precedente

2.29

Notizie sul Sentiment di mercato

By Acuity

50%

50%

167 / 340 Classifica in Healthcare

Lexicon Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ago 2026, 19:36 UTC

News

Lexicon Pharmaceuticals received a $10 million milestone payment from Novo Nordisk, bringing total payments to $75 million as shares rise during Monday's session.

21 ago 2026, 19:36 UTC

Lexicon Pharmaceuticals Inc shares are higher in Friday's session, continuing an upward trend since Thursday. The stock remains below its 20-day moving average.

20 ago 2026, 23:56 UTC

Lexicon Pharmaceuticals Inc shares are rising in after-market trading, showing positive momentum despite being below their 20-day moving average. No specific news was identified.

18 ago 2026, 19:31 UTC

Lexicon Pharmaceuticals Inc shares are higher today, driven by significant gains in the Biotechnology sub-sector. The stock is near its one-month high.

13 ago 2026, 19:56 UTC

Lexicon Pharmaceuticals is trading lower today amid no specific news. First-time claims for U.S. unemployment benefits rose, but investor sentiment remains stable.

12 ago 2026, 23:36 UTC

Lexicon Pharmaceuticals Inc's shares are higher in after-market trading, with no specific news identified. Broader market sentiment may be influenced by recent inflation data.

11 ago 2026, 23:26 UTC

Lexicon Pharmaceuticals Inc. shares are lower in after-market trading, with no specific news identified. Broader market sentiment remains cautious amid oil price developments.

10 ago 2026, 19:56 UTC

News

Lexicon Pharmaceuticals reported a second-quarter earnings loss of -$0.06 per share, missing expectations. Shares are lower amid a downgrade to “sell” from Wall Street Zen.

7 ago 2026, 22:01 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market hours, continuing a notable decline since Friday's close, with no specific news identified to explain the movement.

6 ago 2026, 23:26 UTC

Lexicon Pharmaceuticals shares are trading higher in after-market hours, following three consecutive sessions of declines. No specific news was identified for the price movement.

5 ago 2026, 19:36 UTC

News

Lexicon Pharmaceuticals Inc shares are lower as investors adjust positions ahead of Q2 earnings on August 5, with consensus EPS estimates at -$0.05.

4 ago 2026, 19:56 UTC

Lexicon Pharmaceuticals shares are higher today, reflecting strong momentum amid easing inflation concerns from declining crude oil prices. No specific news was identified.

31 lug 2026, 19:46 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reflecting broader market trends amid rising yields and crude oil prices contributing to inflation concerns.

30 lug 2026, 23:11 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market hours. The decline follows broader market uncertainty after the Federal Reserve's interest rate decision.

29 lug 2026, 21:02 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market declines amid rising oil prices and geopolitical tensions in the Middle East.

27 lug 2026, 19:03 UTC

Lexicon Pharmaceuticals Inc is trading lower today, breaking a trend of higher daily closes. Broader market declines and falling oil prices may influence sentiment.

24 lug 2026, 20:07 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reversing from earlier gains amid broader market volatility influenced by falling oil prices and inflation concerns.

22 lug 2026, 19:02 UTC

Lexicon Pharmaceuticals Inc shares are lower today, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

21 lug 2026, 19:42 UTC

Lexicon Pharmaceuticals is higher as the market gains momentum, driven by strong performances from major companies and a resurgence in semiconductor stocks.

20 lug 2026, 19:06 UTC

Lexicon Pharmaceuticals Inc shares are lower today, following three days of gains. Broader market declines are linked to rising US Treasury yields and oil prices above $90.

Confronto tra pari

Modifica del prezzo

Lexicon Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

156.41% in crescita

Previsioni per 12 mesi

Media 6 USD  156.41%

Alto 6 USD

Basso 6 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lexicon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

167 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
help-icon Live chat